Antengene to Showcase Innovative Clinical Findings at ASCO 2025 Conference

Antengene to Present Revolutionary Findings at ASCO 2025

Antengene Corporation Limited, an innovative biopharmaceutical firm based in Shanghai and Hong Kong, has announced it will unveil its latest findings at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting scheduled from May 30 to June 3, 2025, in Chicago, Illinois. With a focus on transformative therapies for hematologic malignancies and solid tumors, Antengene aims to push forward the boundaries of cancer treatment through its research on novel small molecule inhibitors.

Presentations Overview

Antengene will be presenting crucial data on two of its investigational therapies:
1. ATG-037: A CD73 small molecule inhibitor
2. ATG-008: An mTORC1/2 small molecule inhibitor

ATG-037 Presentation

The poster for ATG-037 will detail a Phase I/Ib clinical study investigating the drug both as a monotherapy and in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This trial targets patients with anti-PD-1 resistant solid tumors, showcasing promising results particularly in melanoma and non-small cell lung cancer (NSCLC). The study aims to optimize dosages, currently ongoing in China and Australia during its expansion phase.
- Title: A first-in-human phase I/Ib study of ATG-037 monotherapy and combination therapy with pembrolizumab in patients with advanced solid tumors.
- Abstract Number: 3123
- Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
- Date & Time: June 2, 2025, from 1:30 PM to 4:30 PM CT (2:30 AM to 5:30 AM June 3, 2025, Beijing Time)

ATG-008 Presentation

The second poster focuses on ATG-008, which is being assessed for its effectiveness in advanced cervical cancers previously treated with anti-PD-(L)1 therapy. This trial combines onatasertib with toripalimab, indicating Antengene's commitment to tackling cervical tumors with innovative treatment modalities.
- Title: A TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced cervical cancers with prior anti-PD-(L)1 therapy.
- Abstract Number: 5540
- Session: Gynecologic Cancer
- Date & Time: June 1, 2025, from 9:00 AM to 12:00 PM CT (10:00 PM June 1, 2025, to 1:00 AM June 2, 2025, Beijing Time)